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Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome (MetS). The aim of the study was
to evaluate the effects of Chinese herbal extracts from Salvia miltiorrhiza and Gardenia jasminoides (SGE) on the combination of
NAFLD and MetS induced by a high-fat diet (HFD) in rats. After 6 weeks of HFD feeding, rats (𝑛 = 10 each group) were treated
with saline, rosiglitazone (RSG), and SGE for 4 weeks. HFD rats were obese, hyperinsulinemic, hyperlipidemic and increased
hepatic enzymes with the histological images of NAFLD. Treatment with SGE significantly reduced serum triglycerides (TG),
nonesterified fatty acids and enhanced insulin sensitivity, and ameliorated the elevated serum hepatic enzymes compared with
HFD-saline group. SGE treatment also attenuated hepatic TG by 18.5% (𝑃 < 0.05). Histological stains showed SGE decreased lipids
droplets in hepatocytes (𝑃 < 0.05) and normalized macrovesicular steatosis in HFD rats. Significant reduction of TNF-𝛼 and IL6
in adipose tissue was detected in SGE treated rats. The anti-inflammatory action may be, at least in part, the mechanism of SGE on
MetS associated with NAFLD. This study discovered that SGE is capable of managing metabolic and histological abnormalities of
NAFLD and MetS. SGE may be an optimal treatment for the combination of NAFLD and MetS.
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is a pathologic
entity, including a spectrum of liver damage ranging from
simple steatosis to non-alcoholic steatohepatitis (NASH),
advanced fibrosis, and progression to cirrhosis [1]. Patho-
physiology of NAFLD still has not been completely clarified
but a large body of clinical and experimental evidence sug-
gests that ectopic fat deposition in the liver plays a fundamen-
tal role in the development and progression of NAFLD [2–
4]. The increased hepatocellular lipids are correlated to cen-
tral obesity, insulin resistance, dyslipidaemia, and impaired
glucose tolerance, a cluster of metabolic syndrome (MetS)
[5, 6]. The prevalence of NAFLD has reached epidemic pro-
portions in recent years, in parallel with the increasing preva-
lence of obesity and MetS worldwide. NAFLD is currently
conceptualised as the hepatic manifestation of MetS, and it
is an early warning sign of future risk for type 2 diabetes and
cardiovascular disease [5–8].
Given the rising coincidence of MetS and NAFLD,
development of an effective treatment for obesity-related
NAFLD to prevent future disease-related morbidity and
mortality is a priority. To date, intervention for MetS
and NAFLD remains mainly lifestyle modifications and no
pharmacological treatment has been proven to be effec-
tive for NAFLD associated with MetS. The pathogenesis
of the combination of NAFLD and MetS is multifactorial,
including hepatic insulin resistance, increased ectopic fat
deposition in the liver and other non-adipose tissues, and
adipocytokines-trigged inflammation [9]. Thus, novel ther-
apy for the disease should be capable of managing insulin
resistance, lowing hyperlipidaemia and anti-inflammation
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as well rendering benefits on liver histological outcomes
[10].
Chinese HerbalMedicine (CHM) has been used in China
and other parts of Asian counties for thousands of years. A
special feature of Chinese medicine is the use of a formula
containing several herbs (like a cocktail) to ameliorate a
set of abnormalities related to a disease. Herbal extracts
contain multiple naturally occurring compounds that can
target different pathological pathways involved in the disease,
providing therapeutic effects via a spectrum of actions. In
our previous study, we demonstrated that a Chinese herbal
formula, containing a high amount of Salvia miltiorrhiza
Bge extract, effectively reversed metabolic syndrome in a
high-fatdiet (HFD) [11]. The dried root of Salvia miltiorrhiza
(S. miltiorrhiza) is a Chinese herb commonly included in
prescriptions to ischemic heart disease, hyperlipidaemia [12,
13], and chronic liver disease [14]. The fruit of Gardenia
jasminoides (G. jasminoides) is a Chinese herb for cleaning
away toxicity in TCM. Recent study showed that the active
ingredient of G. jasminoides (geniposide) has an alleviating
effect on fatty liver in obese diabetic mice [15]. Based on our
previous study and other’s findings, we combined the extracts
from S. miltiorrhiza and G. jasminoides and evaluated their
effects on the coexisting NAFLD and MetS induced by HFD
feeding in rats.
2. Materials and Methods
2.1. Preparation of Chinese Herbal Extracts. Chinese herbal
extracts of S. miltiorrhiza and G. jasminoides were prepared
by Kanion Pharmaceuticals (Lianyungang, Jiangsu, China).
In general, each dried herb was authenticated using micro-
scopic examination to ascertain the species’ authenticity.
Ground herbs were first extracted for 2 h with 65% aqueous
ethanol at room temperature followed by 2 h decoction at
120∘C. The result was then vacuum-filtered through a filter
paper and concentrated in a rotating vacuum evaporator
(Yahya Rong Biochemical Instrument, Shanghai, China) at
40∘C. The highly concentrated solution was freeze-dried to
obtain a solid powder with a yield of 8% and 10% (powder
versus raw herb, w/w) for Salvia root and Gardenia fruit,
respectively. The quality control for the herbal extracts was
performed using an Agilent 1200 series liquid chromatogra-
phy/mass selective detector equipped with QTOF 6510 mass
spectrometer (Agilent Technologies Inc., CA, USA) with
botanical markers of tanshinone IIA for S. miltiorrhiza and
gypenoside for G. jasminoides obtained from the Beijing
Institute of Materia Medica. The content of tanshinone IIA
and gypenoside in 1 g of herbal extract was 120mg and 30mg,
respectively.Themixture of S. miltiorrhiza andG. jasminoides
extracts, coded as SGE, was used for animal study.
2.2. Animals and Treatment. Male Sprague-Dawley (SD) rats
at 6 weeks of age were supplied by the Animal Resources
Centre (Perth, Australia). All experimental procedures were
approved by the University of Technology Sydney Ani-
mal Ethics Committee, following guidelines issued by the
National Health and Medical Research Council of Australia.
SD rats were maintained on a 12 h light/dark cycle (lights
on 0600) under constant temperature (22∘C) with ad libitum
access to standard chow diet or a high-fat diet (HFD, 59% fat,
21% protein, and 20% carbohydrate by energy composition)
for 6 weeks to induce MetS and NAFLD. After 6 weeks of
HFD feeding, HFD fed rats were randomly divided into three
groups (𝑛 = 10 each group) to receive saline 5mL/kg of body
weight (HF-Con), rosiglitazone (HFD-RSG, 3mg/kg of body
weight), and SGE (HFD-SGE, 2 g/kg of body weight) by daily
oral gavage for 4 weeks. HFD feeding continued during the 4-
week treatment period. Meanwhile, saline (5mL/kg of body
weight) was administrated to chow fed rats (chow, 𝑛 = 10) as
the model control.
2.3. Determination of Metabolic Parameters, Liver Enzymes,
and Insulin Sensitivity. At the end of treatment, blood sam-
ples were collected from the tail of rats after an overnight
fast (12 hours). Fasting serum total cholesterols (TCs), high-
density lipoprotein cholesterol (HDL-C), triglycerides (TGs)
and nonesterified fatty acids (NEFAs) were analysed using
enzymatic colorimetric kits obtained from Roche Diagnostic
(Mannheim, Germany) and Wako Pure Chemical Industries
(Japan), respectively. Low-density lipoprotein cholesterol
(LDL-C) concentrations were calculated by Friedewald’s
formula: LDL-C (mmol/L) = TC−HDL-C−TG/2.2 [16].
Fasting serum insulin concentration was measured using
a RIA kit (Linco Diagnostic Services). Fasting serum glu-
cose, alanine aminotransferase (ALT), and aspartate amino-
transferase (AST) were determined by spectrophotometric
analysis using commercial kits (Dialab, Vienna, Austria).
All experimental assays were carried out according to the
manufacturer’s instruction.
Whole-body insulin sensitivity was estimated using the
homeostasis model assessment of insulin resistance (HOMA-
IR) by using the formula: [fasting serum glucose (mmol)
times fasting serum insulin (mU/mL)]/22.5 [17]. Because
HOMA is negatively correlated with insulin sensitivity, low
HOMA-IR values indicate high insulin sensitivity, whereas
high HOMA-IR values indicate insulin resistance.
2.4. Tissue Collection and Measurement of Liver Triglycerides.
At the endof the experiment, animalswere anesthetized using
inhalant aesthetic gas (isoflurane and nitrous oxide) after
12 h of fasting. Liver and visceral fat (epididymal and peri-
rental adipose tissues) were quickly excised, washed by ice-
cold PBS, then stored at −80∘C for subsequent histological
and molecular assays.
Approximately 50mg of liver tissues was homogenized at
4∘C in RIPA lysis buffer (Sigma-Aldrich, St. Luis, MO, USA).
Lipids from total liver andmuscle homogenatewere extracted
using chloroform/methanol method (2 : 1), evaporated, and
dissolved in 1mL ethanol (Sigma-Aldrich). TG concentration
was assayed using kits from Roche Diagnostic (Mannheim
Germany) following the manufacturers’ instructions.
2.5. Measurement of Adipokines. Frozen epididymal fats
(200mg) were homogenized in 1mL lysis buffer containing
150mM NaCl, 1mM PMSF, 10% Glycerol, and the complete
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Table 1: Summary of metabolic parameters in chow and HFD fed rats with variety of treatments.
Chow HFD-Con. HFD-RSG HFD-SGE
Initial body weight, g 372 ± 16 414 ± 14† 409 ± 20 417 ± 16
Final body weight, g 412 ± 22 468 ± 19† 483 ± 32 438 ± 27∗
Visceral fat mass, g 7.8 ± 1.2 14.60 ± 1.20‡ 17.0 ± 1.4 8.9 ± 1.0∗∗
Liver wt, g 11.7 ± 0.2 12.50 ± 0.90 13.3 ± 0.6 11.8 ± 0.6
Serum glucose, mM 6.75 ± 0.14 8.87 ± 0.24‡ 7.65 ± 0.14∗ 8.15 ± 0.18
Serum insulin, mU 26.60 ± 0.22 46.25 ± 0.35‡ 24.01 ± 0.18∗∗ 27.03 ± 0.31∗∗
HOMA-IR 7.98 ± 0.09 18.23 ± 0.28‡ 8.16 ± 0.17∗∗ 9.76 ± 0.29∗∗
Serum TC, mM 3.98 ± 0.21 5.67 ± 0.24† 5.13 ± 0.32 4.35 ± 0.18∗
Serum TG, mM 0.41 ± 0.03 1.03 ± 0.06† 0.59 ± 0.03∗ 0.51 ± 0.02∗∗
Serum HDL-C, mM 1.20 ± 0. 22 0.86 ± 0.13‡ 0.90 ± 0.16 0.96 ± 0.15
Serum LDL-C, mM 2.59 ± 0.52 4.34 ± 0.59‡ 3.96 ± 0.67 3.16 ± 0.56∗
Serum NEFA, mM 0.50 ± 0.10 0.77 ± 0.21† 0.57 ± 0.12∗ 0.58 ± 0.12∗
Data are means ± SEM; 𝑛 = 10 rats/group. †𝑃 < 0.05, ‡𝑃 < 0.01 versus chow control; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 compared with HFD-Con. HOMA is
defined as (fasting insulin × fasting glucose)/22.5. Visceral fat included epididymal fat pad and inguinal fat. TC: total cholesterol; TG: triglycerides; HDL-C:
high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NFFA: nonfree fatty acids.
protease inhibitor cocktail (Roche Diagnostics, Indianapolis,
IN, USA).The homogenates were incubated on ice for 30min
and spun at 10,000 g at 4∘C for 10min. The supernatant was
collected for analysis of leptin, necrosis factor-𝛼 (TNF-𝛼),
interleukin 6 (IL6) in fat tissue using multiplex rat adipocyte
Linoplex kits obtained from Linco Research (Millipore, St.
Charles, MO) for the simultaneous quantification of leptin,
IL-6, and TNF-𝛼 according to themanufacturer’s instruction.
Resulting leptin, TNF-𝛼, and IL-6 contents were determined
using a multiplex reader (BioRad Bio-Plex 200 System; Bio-
rad Laboratories, Hercules, CA, USA) and expressed as nM
in mg of fat tissue.
2.6. Histological Analysis. A small portion of frozen liver
tissue was cut and embedded with precooled optimal cutting
compound (Torrance, CA, USA) for cryostat sectioning at
6 𝜇m.The sections were mounted on microscope slides then
fixed with 10% formaldehyde solution for 48 h. The samples
were then stainedwithHaematoxylin andEosin (H&E) orOil
Red O (Sigma-Aldrich) to investigate architecture of the liver
and hepatic lipid droplets. Stained Oil Red O (ORO) slides
were visualized with the Olympus microscope, and images
were capturedwith anOlympus digital camera (DP70, Tokyo,
Japan) using Image-Pro6.2 software (MediaCybernetics, Inc.,
MD, USA). Lipid droplets was quantified at least 5 different
high-power fields in a blinded way. Masson’s Trichome (MT)
stain was used for evaluation of liver fibrosis. For each
group, liver samples from 6 to 8 rats were prepared and
stained and six fragments from each liver were analysed. All
slides were scanned at an absolute magnification of 200x
using Image-Pro6.2 software (Media Cybernetics) under
a light microscopy (Olympus, BX51 microscope, Tokyo,
Japan).
2.7. Statistical Analysis. All values are expressed as the
means ± SEM. Comparisons across the four groups were
done using one-way ANOVA followed by post-hoc analysis
of Tukey’s test to determine significant differences between
the two groups using Prism version 4 (GraphPad Inc., San
Diego, CA, USA). P-value <0.05 was considered statistically
significant.
3. Results
3.1. Effects of SGE onMetabolic Profiles and Insulin Sensitivity.
HFD feeding significantly increased body weight and visceral
fat mass compared with chow fed rats (Table 1). Weight gain
in SGE group was significantly lower than that in HFD
control rats and RGS treated rats (𝑃 < 0.01). SGE treatment
also markedly reduced visceral fat mass by 46% (𝑃 < 0.01).
The liver weights were not significantly different amongst
three groups of HFD rats, though SGE slightly reduced liver
weight. After a total of 10 weeks of HFD feeding, SD rats
became mildly hyperglycaemic, and SGE treatment reduced
fasting serum glucose levels by 8%, but the reduction did
not achieve a statistical significance (Table 1). SGE reduced
serum TC, TG, and NEFA levels by 23.2% (𝑃 < 0.05),
51.4% (𝑃 < 0.01), and 22.3% (𝑃 < 0.05), respectively, when
compared with the HFD control. LDL-C concentrations
were also decreased in SGE-treated HFD-rats (𝑃 < 0.05).
SGE also raised HDL-C levels by 11.6% compared to HFD
control, but the statistical significance was not achieved. HFD
rat was insulin resistant reflected by hyperinsulinaemia as
well as significantly increased value of Home-IR (Table 1).
SGE treatment produced a similar effect to RGS on insulin
resistance, evidenced by reduction of fasting serum insulin
levels and improved HOME-IR (Table 1).
3.2. SGE Reduced Hepatic Triglycerides and Ameliorated the
Elevated Liver Enzymes of HFD Rats. Figure 1(a) showed that
HFD feeding increased hepatic TG by 2.2-fold compared to
chow fed rats (15.34 ± 0.23 𝜇M/g versus 7.11 ± 1.10 𝜇M/g).
SGE treatment significantly attenuated the elevated hepatic
TG levels by 18.5% (𝑃 < 0.05, compared with HFD-Con.),
and there was no significant reduction of hepatic TG in RSG
treated rats (Figure 1(a)).
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Figure 1: Hepatic triglyceride contents (a), serum alanine aminotransferase (b), and aspartate aminotransferase (c) values in chow fed rats
and HFD control rats treated with saline (5mL/kg of body weight), and HFD rats treated with rosiglitazone (HFD-RSG, 3mg/kg of body
weight) or SGE (HFD-SGE, 2 g/kg of body weight). Data are means ± SEM; 𝑛 = 10 rats/group. †𝑃 < 0.05, ‡𝑃 < 0.01 versus chow control;
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 compared with HFD-Con.
Figures 1(b) and 1(c) showed that serum ALT and AST
concentrations in HFD fed rats were significantly higher than
those in chow fed rats (27.2 ± 1.3 and 31.18 ± 1.66U/L versus
8.3 ± 0.6 and 16.92 ± 0.79U/L, resp.). The RSG treatment had
further increased ALT levels (36.22 ± 1.30U/L). In contrast
to RSG, SGE treatment significantly attenuated the elevated
ALT and AST values to 11.01 ± 0.61U/L (𝑃 < 0.01 versus
HFD-Con.) and 17.3 ± 2.1U/L (𝑃 < 0.05 versus HFD-Con.).
3.3. Effects of SGE on Adipokines. Leptin, TNF-𝛼, and IL-
6 were determined in adipose tissue of chow fed rats and
HFD rats treated with saline, RGS, or SGE, respectively. As
shown in Figure 2, HFD feeding significantly increased TNF-
𝛼 by 26.5% and IL-6 by 49.8% and decreased leptin levels by
81.6%when comparedwith chow fed rats. Both SGE and RGS
were capable of significantly inhibiting HFD-induced TNF-
𝛼 and IL-6 (Figures 2(b) and 2(c), 𝑃 < 0.05 and 𝑃 < 0.01
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Figure 2: Effects of SME on leptin (a), TNF-𝛼 (b), and IL-6 (c) expression in adipose tissue of chow fed rats andHFD control rats treated with
saline (5mL/kg of body weight), and HFD rats treated with rosiglitazone (HFD-RSG, 3mg/kg of body weight) or SGE (HFD-SGE, 2 g/kg of
body weight). Adipose leptin, TNF-𝛼, and IL-6 were determined using a multiplex rat adipocyte Linoplex kit stated in method section. Data
are means ± SEM; 𝑛 = 10 rats/group. †𝑃 < 0.05, ‡𝑃 < 0.01 versus chow control; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 compared with HFD-Con.
versus HFD control, resp.). SGE treatment also significantly
increased leptin expression (𝑃 < 0.05 versus HFD control) in
adipose tissue of HFD rats.
3.4. SGE Improved Fatty Liver, Liver Steatosis, and Fibro-
sis. The photomicrographs of the H&E stain showed that
HFD feeding increased hepatic fat deposits, evidenced by
the majority of the hepatocytes of HFD rats that were
distended by fat in comparison to the chow group (Figures
3(a) and 3(b)). The images of H&E stain also displayed
macrovesicular steatosis, as many single large droplets had
displaced the nucleus and ballooning degeneration causing
conspicuous swelling of the cell and cytoplasmic vacuo-
lation as shown in Figure 3(b). The treatment of HFD
rats with RGS and SGE reduced fat liver depots (Figures
3(c) and 3(d)). The SGE groups showed histological fea-
tures similar to the chow group with no macrovesicu-
lar steatosis as revealed in the HFD group as shown in
Figure 3(b).
ORO staining on frozen liver sections exhibited many
lipid droplets in liver sections of HFD fed rats (Figure 4(b)),
whereas a few lipid droplets were seen in the liver sections
from the chow (Figure 4(a)) and SGE treated HFD rats
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(a) (b)
(c) (d)
Figure 3: Representative images of hematoxylin and eosin (H&E) staining to visualize architecture of the liver and hepatocytes on sections
of the liver section (6𝜇m thick) from chow fed rats (a) and HFD control rats (b) treated with saline (5mL/kg of body weight), and HFD
rats treated with rosiglitazone (RSG, 3mg/kg of body weight, (c)) or SGE (2 g/kg of body weight, (d)). All photomicrographs were taken at a
magnification of 200x. The scale bar represents 50 𝜇M. Data are means ± SME, 𝑛 = 6–8.
(Figure 4(d)). Strikingly, there was an increase in the lipid
content of liver tissue in HFD-RSG rats (Figure 5(c)).
Analysis of blindly scored ORO-stained sections showed
a statistically significant increase in the lipid content of
liver tissue of HFD rats (Figure 4(e)). Levels of lipids were
higher in the liver of HFD rats (10.77 ± 0.45%) compared
with those in chow group (8.80 ± 0.34%). The RSG group
had elevated levels of lipids (9.78 ± 0.21%), similar to
the HFD fed group. The SGE treatment significantly low-
ered lipids values (9.10 ± 0.34%, 𝑃 < 0.05 versus HFD
control).
In the photomicropictographs of Masson’s Trichrome
stain taken in the chow group displayed no fibrotic changes
in the hepatocytes (Figure 5(a)). In theHFDgroup, intracyto-
plasmic fat was seen as clear vacuoles around the vessels and
more distinct and slight fibrotic tissues were stained blue as
shown in Figure 5B. In RSG treated HFD rats, fibrosis were
observed around the vessels by the purplish green colour
in comparison to chow fed rats (Figures 5(c) and 5(a)).
SGE treated rats showed similar histological features in MT
staining as chow fed rats (Figures 5(d) and 5(a)).
4. Discussion
As with our previous study, feeding a high-fat diet to SD
rats led to visceral obesity associated with hyperlipidaemia,
hyperinsulinaemia, and slight hyperglycaemia, which are
characteristics of metabolic syndrome [11]. In the present
study, we have demonstrated those ten weeks of high-fat
diet feeding induced fatty liver disease in SD rats. The
HFD fed rats assembled key biochemical features of MetS
and NAFLD, including hyperinsulinaemia and increased
HOMRE-IR value, marked elevation of hepatic enzymes,
and hyperlipidaemia associated with increased TG accumu-
lation in the liver. Histological evaluation remains the most
important method of identifying NAFLD lesions, includ-
ing steatosis, lobular and portal inflammation, hepatocyte
injury as ballooning, and fibrosis [18]. In the present study,
H&E, MT, and ORO stains on the liver samples revealed
distended hepatocytes with increased lipid droplets, macro-
vesicular steatosis, indicating the simple steatohepatitis and
mild fibrosiswith no cirrhotic displacements.Thehistological
abnormalities in the HFD rats of this study were consistent
Evidence-Based Complementary and Alternative Medicine 7
(a) (b) (c)
(d)
0
2
4
6
8
10
12
Li
pi
ds
 in
 li
ve
r (
ar
ea
 fr
ac
tio
n 
%
)
∗
†
Ch
ow
H
FD
-C
on
.
H
FD
-R
SG
H
FD
-S
G
E
(e)
Figure 4: Representative images of Oil Red O (ORO) staining to visualize lipid droplets on liver sections (6 𝜇m thick) from chow fed rats
(a) and HFD control rats (b) treated with saline (5mL/kg of body weight), and HFD rats treated with rosiglitazone (RSG, 3mg/kg of body
weight, (c)) or SGE (2 g/kg of body weight, (d)). Images from the stained liver were taken at a magnification of 200x.The scale bar represents
50 𝜇M. Lipid droplets quantified at least 5 different high-power fields, being blind by two independent assessors. The intensity of staining of
liver tissue with ORO provides a qualitative measure of the lipid contents (e). Data are means ± SEM, 𝑛 = 6–8, †𝑃 < 0.05, ‡𝑃 < 0.01 versus
chow control; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 compared with HFD-Con.
with the findings of the previous literatures [19, 20]. High fat
diet induced animal model of NAFLD has been widely used
to identify the pathogenesis and evaluate new treatment for
NAFLD [20, 21].
The elevated liver aminotransferase is a nonspecific
clinical feature of NAFLD, which positively correlated to
90% patients with NASH [22]. Treatment with SGE for 4
weeks has proven to significantly normalise the liver hepatic
aminotransferase (ALT and AST) to the level as normal
chow control. Specifically, SGE treatment was effective in
impeding fat infiltration (evidenced by decreased hepatic TG
contents and lipid droplets) and preventing hepatic fibrosis,
as shown in similar histological appearances as the chow
control group. The results from biochemistry and histology
assays demonstrated that SGE was protective against HFD-
induced liver lesion and prevented NAFLD in HFD rats.
NAELD’s pathogenic mechanisms are still under inves-
tigation; however, fat accumulation, mainly triglycerides
filtrationwithin hepatocytes, is considered the first step in the
development of NAFLD [23]. The clinical and animal studies
demonstrated that levels of hepatic triglycerides are positively
correlated to visceral obesity and insulin resistance [4, 24].
Under insulin resistant status, FFAs from lipolysis of visceral
tissue are increased with decreased oxidative capacity. The
elevated FFAs in the blood stream will directly circulate into
the portal vein where the liver deposits FFAs as triglyceride
in the hepatocytes and contribute to liver fibrosis. In addition
to over-accumulation of triglycerides, de no synthesis of
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Figure 5: The photomicropictographs of Masson’s Trichrome staining for assessment of the degree of fibrosis in the liver section from chow
fed rats (a) and HFD control rats (b) treated with saline (5mL/kg of body weight), and HFD rats treated with rosiglitazone (HFD-RSG,
3mg/kg of body weight, (c)) or SGE (HFD-SGE, 2 g/kg of body weight, (d)). All photomicrographs were taken at 200x magnification.
unoxidised fatty acids (ceramides and diglycerides) in the
liver also increases, which trigger apoptosis of lipid-laden
hepatocytes and impair insulin signal pathway. Therefore,
aggressive treatment of hyperlipidaemia and inhibition of
adipose lipolysis play a critical role in the overallmanagement
of patients with NAFLD and MetS. Statins are the first-line
agents to treat hyperlipidaemia but there is a risk for liver
injury in patients with NAFLD [25]. Ten weeks of HFD
feeding in rats caused atherogenic dyslipidaemia with high
levels of TG, low levels of HDL-C, and marked elevations
in LDL-C concentrations. In this study, we showed that
SGE had effects on hypertriglyceridemia and attenuated the
elevated serum NEFAs, indicating that SGE may inhibit
adipose lipolysis or enhanced FFAs availability. SGE also
presented similar effects to RSG (insulin sensitizer) on
hyperinsulinaemia and improved HOME-IR, but its potency
was much less than RSG as the higher dose (2 g/kg of body
weight) than RSG (3mg/kg of body weight) was needed.
SGE also raised HDL-C levels; however, the statistical sig-
nificance was not achieved. Increasing the proportion of
S. miltiorrhiza may be necessary if the formula would target
at atherogenic dyslipidemia because the previous study has
shown that S.miltiorrhizamarkedly raisedHDL-C in patients
with ischemic cerebrovascular disease [12]. Specifically, we
demonstrated that SGE had a beneficial effect on body weight
and significantly reduced visceral fat mass but RSG treated
rats gained more weight than HFD control. Thus, present
study has proven that SGE had preventive effect on NAFLD
as well as improved several metabolic abnormalities in HFD
rats.
Accumulating data demonstrate that obesity and insulin
resistance lead to NAFLD and hepatic fibrosis through
not only fatty infiltration but also adipocytokines-induced
inflammation [26]. Adipocytokines are cytokines secreted
primarily by adipose tissue, including adiponectin, leptin,
resistin, TNF-𝛼, interleukins, and others.Decreased secretion
of adiponectin and leptin from adipose tissue is involved in
central obesity and insulin resistance [27]. Leptin is a key fat-
derived hormone produced by adipose tissue, acting on the
brain to increase satiety, hence inhibiting food intake and
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controlling weight gain [28]. After a high-fat meal, leptin
secretion usually increased in rodents [29]. Our study showed
that chronic HFD feeding was associated with reduced leptin
expression in adipose tissue. This reduced leptin levels may
contribute to the subsequent weight gain that we observed
in the control HFD rats. We propose two mechanisms that
may explain why a high dietary fat intake was associated
with decreased leptin expression. Firstly, a long-term high-
fat exposure (10 weeks) may overstimulate leptin secre-
tion, hence depleting leptin contents in the adipose tissue.
Secondly, increases in lipolysis have also been associated
with decreased leptin synthesis in the previous study [30].
Decreased leptin synthesis may explain reduced leptin levels
in adipose tissue after fat feeding because increased lipol-
ysis has been documented after high-fat diets [31]. Our
study has demonstrated that SGE treatment enhanced leptin
expression, which is consistent with a recent study that
circulating leptin was reversely associated with weight loss
and VLDL-TG secretion in obese subjects [32]. Furthermore,
the marked hepatic steatosis has been observed in leptin-
deficient ob/obmice [33]. Enhanced leptin expressionmay be
one of mechanisms by which SGE ameliorated NAFLD and
hepatic fibrosis in HFD rats.
Overexpression of TNF-𝛼 and IL6 has been identified
in the adipose tissue of obese patients [34]. TNF-𝛼 together
with IL6 can mediate macrophage infiltration locally and at
distant sites, such as liver. Hepatic inflammation resulting
from adipose proinflammatory cytokines plays an important
role in the development of NAFLD and progression of the
fibrogenic process [35]. In the present study, HFD feeding
significantly increased the weight of visceral fat and insulin
resistance. In particular, decreased leptin and increased
TNF-𝛼 and IL6 expression in visceral fat were found in HFD
rats compared with standard chow fed rats. Treatment with
both SGE and RGS significantly inhibited adipose TNF-𝛼
and IL6 expression but only SGE increased leptin expression
in adipose tissue. Anti-inflammatory action may be one
of the mechanisms that SGE attenuate HFD-induced liver
pathology.
The coexisting MetS and NAFLD provide a rationale
for using a formula with multiple naturally occurring
compounds that can target different pathological pathways
involved in this complicated metabolic disorder, providing
therapeutic effects via a spectrum of actions. SGE contains
active compounds existing in S. miltiorrhiza such as 3,
4-dihydroxyphenyl lactic acid (named as Danshensu) and
diterpenoid quinines (tanshinone IIA) from S. miltiorrhiza,
and active compounds such as geniposide and genipin from
G. jasminoides. The previous studies have demonstrated
that the active compounds in S. miltiorrhiz ahave beneficial
effects on the cardiovascular system through reducing oxi-
dant stress, inhibiting inflammatory cytokine (plasminogen
activator inhibitor-1), and improving lipid profiles [12, 13,
36]. The results in this study may also account for the
pharmacological action of ingredients from G. jasminoides.
Geniposide is one of the major iridoid glucosides in the
fruit of G. jasminoides, which has been reported to possess
anti-inflammatory activity [37]. A recent animal study has
demonstrated that geniposide has an antiobesity effect, and
the metabolite genipin shows a direct effect on the fatty
liver through inducing expression of a lipid metabolism-
related gene [15].We have performed screening tests onmany
herbal extracts from single herb, but their actions were mild
and lack of the capability to control most components of
metabolic syndrome (data not published). The SGE used in
this study have substantially exemplified that the effects of
natural compounds together may provide synergistic effects.
In summary, this study demonstrated that SGE improved
circulating lipid profiles, reduced visceral fat, and improved
insulin resistance, as well as effectively impeded the accu-
mulation of triglycerides in the liver and fat infiltration
in the hepatocytes with normal histological appearances
and hepatic enzymes in HFD fed rats. SGE prevented the
development of HFD-inducedNAFLDmaybe through atten-
uating release of inflammatory cytokine from adipose tissue.
Because two herbs have been used in TCM for thousand
years, it has been considered for its safety and tolerability.
Large scale of clinical trials is worth being performed to prove
that SGE is an optimal approach to the combination of non-
alcoholic fatty liver disease and metabolic syndrome.
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